TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ('NurExone” or the 'Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce today that its wholly owned U.S. subsidiary, Exo-Top Inc. ('Exo-Top”), has entered into a binding memorandum of understanding (the 'MOU”) setting out the principal commercial terms for a proposed definitive distribution agreement (the 'Definitive Agreement”) with ExoLyra LLC, which operates as an arm’s length third party ('ExoLyra”).